Carl Schmid and Frank J. Palella, MD, discuss how coverage differs for medications vs ancillary service costs for HIV PrEP based on USPSTF guidelines. Ryan Haumschild, PharmD, MS, MBA: I’m going to ...

Sean E. Bland, JD, reviews the USPSTF guidelines as support to access HIV PrEP therapy and Ryan Bitton, PharmD, MBA, shares a payer perspective on the implications of these guidelines. Ryan Haumschild ...

A new Canadian guideline on HIV prevention emphasizes the patient’s role in decisions related to pre-exposure prophylaxis (PrEP) and postexposure prophylaxis (PEP) prescriptions. It also highlighted ...

Please provide your email address to receive an email when new articles are posted on . The recommendation is consistent with the task force’s 2022 draft and 2019 final recommendations. Risk factors ...

Oral HIV pre-exposure prophylaxis (PrEP) is highly effective for preventing HIV. Several different developments in the US either threaten to increase or promise to decrease PrEP out-of-pocket costs ...

Multiple pre-exposure (PrEP) and postexposure (PEP) treatments are now available to prevent HIV infection. An updated Canadian guideline published in CMAJ (Canadian Medical Association Journal) ...

The CDC made a strong recommendation based on a high certainty of evidence to use the long-acting injectable lenacapavir (Yeztugo) for HIV pre-exposure prophylaxis (PrEP), but will that ensure the ...

World Health Organisation (WHO) has released new guidelines for the use of long-acting cabotegravir (CAB-LA) as pre-exposure prophylaxis (PrEP) for HIV. Director of WHO’s Global HIV, Hepatitis and ...

The Centers for Disease Control and Prevention (CDC) has come out with a strong recommendation for the use of Gilead Sciences’ twice-yearly HIV pre-exposure prophylaxis (PrEP) med Yeztugo, ...